VGXI Announces Strategic Partnership for Phase III and Commercial-Scale Production of DNA Pharmaceuticals

Share Article

Texas-based CMO, VGXI engages in mutually beneficial partnership to provide the industry with a unified solution for plasmid manufacturing from preclinical through commercial supply.

VGXI Production Facility

VGXI Production Facility

This partnership is ideally suited to meet the growing industry need for DNA pharmaceuticals.

VGXI, Inc., a contract manufacturing organization specializing in GMP plasmid DNA production, announces today that they have entered into a partnership and licensing agreement with a commercial scale manufacturer for GMP plasmid production. According to the agreement, the partnering company will incorporate VGXI’s proprietary plasmid manufacturing and purification technologies for production of DNA-based pharmaceuticals at Phase III to commercial-scale. Technology transfer is already underway and large-scale GMP plasmid production will be available as soon as this process is complete.

“We are extremely pleased to be able to offer this new capability to all of our current and prospective customers” said VGXI CEO, Young Park. “Several clients have expressed a need for increased production volumes, and this partnership will allow commercial scalability until VGXI has established its own large-scale manufacturing facility.”

The gene therapy and DNA vaccine industries have experienced dramatic growth in just the past year, with renewed investment from large pharmaceutical companies, record-breaking IPOs, and recent clinical successes for cancer immunotherapies and next-generation genetic vaccines. As these technologies mature into larger, later-stage clinical trials, it will be critical for the supporting manufacturing industry to keep pace while maintaining consistency in the production process and without sacrificing the quality or purity of the DNA product.

This partnership is ideally suited to meet the growing industry need for DNA pharmaceuticals. Supplying cGMP plasmid products for clients worldwide, VGXI has developed extensive manufacturing expertise and has been repeatedly recognized by the industry for the quality of its CMO services and DNA products. The Texas-based organization has already demonstrated reliable scalability of its patented AIRMIX™ lysis technology across fermentation capacities from 10L to 500L volume. Through the license agreement, the AIRMIX™ continuous, low-shear cell disruption technology as well as other highly optimized manufacturing techniques will be transferred and further scaled to fermentation capacities of up to 1500L at the European-based plant. As one of the most modern facilities, this plant was purposely designed for biologics manufacturing and is well-suited for commercial scale-up of the VGXI process.

By combining the complementary capabilities of both companies, the strategic partnership announced today will provide the biopharmaceutical industry with a unified DNA manufacturing solution and enable further clinical development of genetic vaccines and therapeutics.

Link to VGXI website for more information on their process and services.

ABOUT VGXI, INC.
With over 15 years of experience, VGXI Inc. is a leading provider of plasmid DNA manufacturing and development services for DNA vaccine and gene therapy research. The company has an outstanding track record of success in manufacturing plasmid products under GMP conditions for clinical trials in the US, EU, Asia and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI is a wholly- owned subsidiary of GeneOne Life Science, Inc. (KRX:011000)

Cautionary Factors That May Affect Future Results – Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Christy Franco
Follow us on
Visit website